Company News
OSB Group tumbles as net interest margin guidance disappoints
OSB Group tumbled on Thursday as full-year profits beat expectations but guidance on net interest margin disappointed.
Eneraqua Technologies FY pre-tax losses seen in line with consensus
Energy and water efficiency solutions provider Eneraqua Technologies said on Thursday that full-year revenues and pre-tax losses were seen in line with consensus forecasts.
Alfa Financial announces another special divi after solid 2023
Shares in Alfa Financial rose on Thursday after the asset finance software group announced a £5. 9m special dividend and an 8% increase in its final dividend following a solid set of annual results and solid cash generation.
Ceres Power results to be delayed by audit
Ceres Power, a developer of clean energy technology, announced a delay in releasing its full-year results for the year ended 31 December on Thursday.
Shell pays CEO £7.9m in first year, makes changes to climate pledge
Energy giant Shell switched up its climate pledge on Thursday and revealed that chief executive Wael Sawan was paid a total of £7. 94m in his first year on the job.
John Lewis swings back into the red
John Lewis Partnership has returned to profit, the retailer confirmed on Thursday, but said it would not pay staff bonuses for the second year running.
Bridgepoint delivers 'strong' FY performance
Private investment firm Bridgepoint delivered a "strong" full-year performance on Thursday and said it was "well placed" for continued growth.
Profits tumble at Savills after 'challenging' year
Property firm Savills posted a slump in annual profits on Thursday, but said it expected to see a recovery in the real estate market later this year.
Wise slides as Valar Velocity places 4m shares
Wise slid on Thursday after shareholder Valar Velocity Fund 1 placed 4m class A shares in the fintech firm via Morgan Stanley.
Symphony Environmental Tech extends convertible loan agreements
Symphony Environmental Technologies announced extensions to its existing convertible loan agreements with Sea Pearl Ventures on Thursday, to 31 December 2025, expanding from the previous end date of 30 September 2024.
Cadence Minerals investee Evergreen reports progress at Bynoe
Cadence Minerals updated the market on its investee company, ASX-listed Evergreen Lithium, on Thursday, after the latter disclosed significant developments in its phase three geochemical soil sampling programme at Bynoe in Australia’s Northern Territory.
Helios Towers delivers strong results, but 2024 guidance underwhelms
Telecoms infrastructure firm Helios Towers has hinted that it is closer to distributing cash back to shareholders and said that 2024 is to be an "inflection year" for free cash flow following a period of busy acquisition activity.
Halma maintains expectations as revenue rises
Halma reiterated its guidance in a trading update on Thursday, maintaining its projection for adjusted profit before tax to align with analyst consensus expectations.
Moonpig trading in line; agrees new revolving credit facility
Greeting cards and gift retailer Moonpig said on Thursday that trading in the current financial year ending 30 April has remained in line with expectations across all of its brands, as it announced a new revolving credit facility.
IG Group announces exit of CFO and COO
Online trading platform IG Group has reported stable revenues in the third quarter as it announced the resignation of both its chief financial officer and chief operating officer, just two months after the appointment of a new chief executive.
Deliveroo narrows losses in 'resilient' year
Deliveroo reported a narrowing of its full-year losses on Thursday as revenue jumped and the company hailed a "resilient year of growth".
Trainline sales, revenues surge on UK, intl demand
Online ticketing platform Trainline reported sales at the top end of expectations as fewer strikes in the UK and competition for passengers in Italy and Spain saw revenues also beat forecasts.
AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn
Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1. 05bn to beef up its late-stage rare disease pipeline.